Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose moxidectin versus ivermectin safety study in onchocerciasis, with albendazole in lymphatic filariasis co-endemic areas
PACTR202003567524647Phase 3Unknown
- Sponsor
- Medicines Development for Global Health
- Start
- Feb 2021
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3 trial of moxidectin, ivermectin and albendazole in onchocerciasis and filariasis (4 arms), sponsored by Medicines Development for Global Health. Primary endpoint: Incidence and severity of treatment emergent adverse events. Status: unknown.
02
Drugs
moxidectinivermectinalbendazole
03
Conditions
onchocerciasisfilariasis
Beyond the preview
Go deeper on PACTR202003567524647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202003567524647.